Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ
- PMID: 20129059
- DOI: 10.1016/j.molcel.2009.12.024
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ
Abstract
The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival. MLN4924 is a selective inhibitor of NAE currently in clinical trials for the treatment of cancer. Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme. The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions. The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924. Importantly, we have determined that compounds resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes. These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Absolute quantification of E1, ubiquitin-like proteins and Nedd8-MLN4924 adduct by mass spectrometry.Cell Biochem Biophys. 2013 Sep;67(1):139-47. doi: 10.1007/s12013-013-9625-5. Cell Biochem Biophys. 2013. PMID: 23754621
-
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.PLoS One. 2014 Apr 1;9(4):e93530. doi: 10.1371/journal.pone.0093530. eCollection 2014. PLoS One. 2014. PMID: 24691136 Free PMC article.
-
Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24. Cancer Res. 2013. PMID: 23100467
-
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. doi: 10.1517/13543784.2012.707192. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799561 Review.
-
Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication.Anticancer Agents Med Chem. 2015;15(9):1127-33. doi: 10.2174/1871520615666150305111257. Anticancer Agents Med Chem. 2015. PMID: 25742093 Review.
Cited by
-
UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer.Transl Oncol. 2020 Nov;13(11):100834. doi: 10.1016/j.tranon.2020.100834. Epub 2020 Jul 17. Transl Oncol. 2020. PMID: 32688248 Free PMC article.
-
Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance.Front Pharmacol. 2020 Aug 7;11:1208. doi: 10.3389/fphar.2020.01208. eCollection 2020. Front Pharmacol. 2020. PMID: 32903706 Free PMC article.
-
Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Oncologist. 2021 May;26(5):406-421. doi: 10.1002/onco.13769. Epub 2021 Apr 21. Oncologist. 2021. PMID: 33792103 Free PMC article. Review.
-
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.J Hematol Oncol. 2022 Aug 31;15(1):124. doi: 10.1186/s13045-022-01346-9. J Hematol Oncol. 2022. PMID: 36045390 Free PMC article. Review.
-
Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review).Int J Oncol. 2024 Apr;64(4):39. doi: 10.3892/ijo.2024.5627. Epub 2024 Feb 23. Int J Oncol. 2024. PMID: 38391033 Free PMC article. Review.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous